Showing results (21-30 of 123) with videos related to
Sort By:
Pageof 13
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 8, 2009
Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failureSonja Merkesdal, Timm Kirchhoff, Diane Wolka, et al.Journal of Medical Case Reports|June 1, 2011
Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case reportAlexander Shimabukuro-Vornhagen, Achim Rothe, Lucia Nogova, et al.Rheumatology and Therapy|March 5, 2018
A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic DiseasesAndrea Rubbert-Roth, Daniel E Furst, Jan Michael Nebesky, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 18, 2004
Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell linesFriederike Heuck, Julia Ellermann, Peter Borchmann, et al.Plos One|December 24, 2010
Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseasesOlaf Schultz, Frank Oberhauser, Jasemine Saech, et al.Journal of Experimental & Clinical Cancer Research : CR|May 18, 2012
The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cellsAlexander Shimabukuro-Vornhagen, Andreas Draube, Tanja M Liebig, et al.Autoimmunity Reviews|November 8, 2017
TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?Andrea Rubbert-Roth, Fabiola Atzeni, Ignazio Francesco Masala, et al.Autoimmunity Reviews|October 23, 2019
Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agentsAndrea Rubbert-Roth, Melinda Zsuzsanna Szabó, Melinda Kedves, et al.Blood|May 10, 2005
The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosisBoris Böll, Hinrich Hansen, Friederike Heuck, et al.Clinical Rheumatology|June 10, 2010
An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX)Norma Jung, Matthias Hellmann, Reimund Hoheisel, et al.Pageof 13